Plasma biomarker clues to HIV reservoir activity in people on ART
Official title: Cross-sectional study to identify host plasma biomarkers and Somalogic disease prognosis scores associated with cellular HIV-1 RNA expression in ART suppressed persons
Funded at Wistar Institute · NIH-11411700 · Data updated 2026-11-12
Researchers will look for blood protein signals that relate to hidden HIV activity in people on antiretroviral therapy.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wistar Institute NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | June 1, 2026 |
| Project end | May 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $506,550 |
| NIH project number | 1R21AI200716-01 |
| Project ID | NIH-11411700 on NIH RePORTER |
Who could benefit from this research
✓Could help
Individuals living with HIV who are on ART and have measurable HIV reservoir activity.
✕Less likely to help
People not on ART or without HIV reservoir activity may not benefit from these findings.
What this research studies
This project will analyze blood samples from people living with HIV who are on ART to see which plasma proteins correlate with cell-associated HIV RNA. Using advanced Somalogic technology, the team will measure thousands of proteins and connect them to predefined HIV reservoir markers. The goal is to identify signatures that could predict future health risks or comorbidities despite successful ART. The study design is cross-sectional, focusing on participants with known HIV reservoir levels to generate new biomarker insights.
Why it matters
Potential benefit: If successful, this work could lead to blood tests that help predict HIV-related health risks and guide personalized care.
How similar studies have gone: Prior work has shown that certain plasma proteins relate to HIV activity, but the exact biomarkers and prognostic links are still being refined.
Where this research is happening
-
Wistar Institute
Philadelphia, United States Active
Researchers
- Principal investigator: Papasavvas, Emmanouil — Wistar Institute
- Study coordinator: Papasavvas, Emmanouil
Related research
Other NIH-funded projects on the same topics.
-
Colorectal cancer prognosis through a broad, collaborative study
A large, multi-center study follows people newly diagnosed with colorectal cancer to find biomarkers and patterns that predict outcomes and guide future care.
-
AI-powered digital pathology to tailor cancer treatment decisions
A team at Emory is building an AI-powered platform that analyzes cancer slides to help doctors choose the right therapies and avoid unnecessary chemotherapy or radiation for patients.
-
Harnessing the body's response to leptospirosis to aid diagnosis and prognosis
This grant aims to develop new ways to detect leptospirosis earlier and predict how severe it might become by studying the body's own response.
-
Harnessing the body’s response to Leptospirosis to improve diagnosis and prognosis
A research program at UCLA aims to use how the body responds to leptospirosis to make better diagnoses and predict outcomes for patients.
-
Harnessing the body's response to a dangerous infection to help diagnose and predict outcomes
A large, multi-project effort aims to use how the body reacts to leptospirosis to improve diagnosis and prognosis for patients affected by this infection.
-
Harnessing the body’s response to leptospirosis for diagnosis and prognosis
A multi-site team is working to develop how the body naturally responds to leptospirosis to improve how we diagnose the infection and predict its course.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.